{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:03:35Z","timestamp":1780297415297,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.trim.2026.102391","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:34:08Z","timestamp":1777577648000},"page":"102391","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chidamide maintenance after allogeneic hematopoietic stem cell transplantation in mycosis fungoides: A case report"],"prefix":"10.1016","volume":"96","author":[{"given":"JiaJuan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YuTing","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiWen","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShengJin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"25","key":"10.1016\/j.trim.2026.102391_bb0005","doi-asserted-by":"crossref","first-page":"6163","DOI":"10.1200\/JCO.2005.02.774","article-title":"Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides","volume":"23","author":"Molina","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.trim.2026.102391_bb0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/sj.bmt.1705968","article-title":"Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma","volume":"41","author":"Duarte","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.trim.2026.102391_bb0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2024.10.119","article-title":"Cutaneous T cell lymphoma arising in patients treated with dupilumab: a case series of 18 patients","volume":"92","author":"Accetta","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.trim.2026.102391_bb0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/s41409-024-02236-z","article-title":"Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for mycosis fungoides and Sezary syndrome","volume":"59","author":"Morris","year":"2024","journal-title":"Bone Marrow Transplant."},{"issue":"11","key":"10.1016\/j.trim.2026.102391_bb0025","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/s41409-022-01787-3","article-title":"Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides","volume":"57","author":"Elliott","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/bjd\/ljaf105","article-title":"Therapeutic advances for cutaneous T-cell lymphoma","volume":"193","author":"Bagot","year":"2025","journal-title":"Br. J. Dermatol."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-021-00296-9","article-title":"Cutaneous T cell lymphoma","volume":"7","author":"Dummer","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.trim.2026.102391_bb0040","doi-asserted-by":"crossref","first-page":"1291259","DOI":"10.3389\/fimmu.2023.1291259","article-title":"Advancements in the treatment of mycosis fungoides and S\u00e9zary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors","volume":"14","author":"Quadri","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0045","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1067\/mjd.2002.122188","article-title":"Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation","volume":"47","author":"Masood","year":"2002","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10392","key":"10.1016\/j.trim.2026.102391_bb0050","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(23)00329-X","article-title":"Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study","volume":"401","author":"de Masson","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.trim.2026.102391_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.bmt.1705741","article-title":"Graft versus lymphoma effect after early relapse following reduced-intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides","volume":"40","author":"Gabriel","year":"2007","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.trim.2026.102391_bb0060","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.bmt.1704641","article-title":"Graft-versus-lymphoma effect in refractory cutaneous T-cell lymphoma after reduced-intensity HLA-matched sibling allogeneic stem cell transplantation","volume":"34","author":"Herbert","year":"2004","journal-title":"Bone Marrow Transplant."},{"issue":"29","key":"10.1016\/j.trim.2026.102391_bb0065","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1200\/JCO.2010.29.3241","article-title":"Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and S\u00e9zary syndrome: a retrospective analysis of the lymphoma working Party of the European Group for blood and marrow transplantation","volume":"28","author":"Duarte","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.trim.2026.102391_bb0070","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1046\/j.1365-2141.2001.02919.x","article-title":"T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement","volume":"114","author":"Olavarria","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0075","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41409-023-02122-0","article-title":"Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis","volume":"59","author":"Goyal","year":"2024","journal-title":"Bone Marrow Transplant."},{"issue":"6","key":"10.1016\/j.trim.2026.102391_bb0080","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/s41409-020-01197-3","article-title":"Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and S\u00e9zary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation","volume":"56","author":"Domingo-Domenech","year":"2021","journal-title":"Bone Marrow Transplant."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0085","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1182\/hematology.2024000670","article-title":"The role of stem cell transplant (auto and Allo) in PTCL and CTCL","volume":"2024","author":"Dreger","year":"2024","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"issue":"2","key":"10.1016\/j.trim.2026.102391_bb0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2025.04.005","article-title":"ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and S\u00e9zary syndrome","volume":"93","author":"Goyal","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"issue":"6","key":"10.1016\/j.trim.2026.102391_bb0095","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/bjd.17535","article-title":"Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement","volume":"181","author":"Doerschner","year":"2019","journal-title":"Br. J. Dermatol."},{"issue":"2","key":"10.1016\/j.trim.2026.102391_bb0100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/jdv.70042","article-title":"Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee","volume":"40","author":"Damaj","year":"2026","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.trim.2026.102391_bb0105","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fmed.2020.00290","article-title":"Long-term disease control after allogeneic hematopoietic stem cell transplantation in primary cutaneous T-cell lymphoma; results from a single institution analysis","volume":"7","author":"Dimitriou","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.trim.2026.102391_bb0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/hon.3088","article-title":"Chidamide: targeting epigenetic regulation in the treatment of hematological malignancy","volume":"41","author":"Cao","year":"2023","journal-title":"Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.trim.2026.102391_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/cells12060952","article-title":"Targeting ARID1A-deficient cancers: an immune-metabolic perspective","volume":"12","author":"Lebedev","year":"2023","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.trim.2026.102391_bb0120","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00277-024-05853-2","article-title":"Prophylactic therapy using epigenetic agents for RUNX1::RUNXT1-positive high-risk AML after Allo-HSCT","volume":"103","author":"Guo","year":"2024","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13148-025-01987-w","article-title":"Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after Allo-HSCT","volume":"17","author":"Wu","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.trim.2026.102391_bb0130","article-title":"Chidamide-based 3-drug combination regimen reverses molecular relapse post transplantation in AML1-ETO-positive acute myeloid leukemia","volume":"13","author":"Xi","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"1","key":"10.1016\/j.trim.2026.102391_bb0135","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","article-title":"Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China","volume":"10","author":"Shi","year":"2017","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.trim.2026.102391_bb0140","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jamadermatol.2025.1926","article-title":"Linperlisib plus Chidamide in relapsed or refractory cutaneous T-cell lymphoma: a nonrandomized clinical trial","volume":"161","author":"Pang","year":"2025","journal-title":"JAMA Dermatol."},{"issue":"40","key":"10.1016\/j.trim.2026.102391_bb0145","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035413","article-title":"Case report: successful treatment of Chidamide in a refractory\/recurrent SPTCL with ARID1A mutation on the basis of CHOP plus auto-HSCT","volume":"102","author":"Zhang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.trim.2026.102391_bb0150","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.17258","article-title":"The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients","volume":"181","author":"Scarisbrick","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.trim.2026.102391_bb0155","doi-asserted-by":"crossref","first-page":"adv10306","DOI":"10.2340\/actadv.v103.10306","article-title":"Use of pegylated interferon alpha-2a in cutaneous T-cell lymphoma: a retrospective case collection","volume":"103","author":"Gosmann","year":"2023","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.trim.2026.102391_bb0160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1091014","article-title":"Preemptive interferon-\u03b1 therapy could prevent relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation: a real-world analysis","volume":"14","author":"Fan","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000493?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327426000493?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T06:48:34Z","timestamp":1780296514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327426000493"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S0966327426000493"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2026.102391","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chidamide maintenance after allogeneic hematopoietic stem cell transplantation in mycosis fungoides: A case report","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2026.102391","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102391"}}